In 33 Japanese T2DM patients treated with tirzepatide for 6 months, HbA1c dropped from 7.3% to 5.8%, body weight fell from 87.7 to 79.6 kg, and eating behavior scores improved — with different improvement patterns depending on prior GLP-1 RA exposure.
Eating score: 57.0→45.9Tirzepatide improved validated eating behavior scores by 19% over 6 months — an effect that did not correlate with weight or glucose changes, suggesting an independent behavioral mechanism
What the researchers found
Over 6 months: HbA1c 7.3%→6.0%→5.8%. Body weight 87.7→82.0→79.6 kg. Eating behavior score 57.0→50.7→45.9. GLP-1RA-naïve (n=20): eating behavior changes mainly in first 3 months. GLP-1RA non-naïve (n=13): eating behavior changes continued through 6 months. No correlation between eating behavior changes and weight/glucose changes.
Why it matters
Weight loss drugs are often criticized as purely metabolic interventions that don't address the behavioral and psychological aspects of overeating. This study suggests tirzepatide may actually change how people relate to food — an effect that appears independent of its metabolic benefits and could contribute to more sustainable weight management.
The numbers in context
33 patients, mean age 51.8 years. Tirzepatide started at 2.5 mg/week for 4 weeks, then 5.0 mg/week, for 6 months total.
How the study worked
Prospective cohort of 33 Japanese T2DM patients (mean age 51.8 years). Tirzepatide 2.5 mg/week for 4 weeks, then 5.0 mg/week. Validated eating behavior questionnaire at baseline, 3 months, and 6 months. Subgroup analysis by prior GLP-1 RA exposure.
Who was studied
Japanese adults with type 2 diabetes
What this study cannot tell us
Small sample (33 patients). No control group. Japanese population with lower BMI and tirzepatide doses than Western studies. Validated questionnaire is subjective. 6 months may not capture long-term behavioral sustainability. Eating behavior assessment doesn't distinguish between hunger reduction and true behavioral change.
How to read the evidence
Rated preliminary: small uncontrolled cohort (33 patients). Interesting signal but needs confirmation in larger controlled studies with objective behavioral measures.
When this study was published
Published in 2024. Addresses the emerging question of GLP-1/GIP drug effects on eating behavior beyond appetite suppression.
The bigger picture
Tirzepatide's dual GIP/GLP-1 action may produce distinct brain effects compared to GLP-1-only drugs. The finding that eating behavior improvements don't correlate with weight loss suggests a direct central nervous system effect on food reward and eating patterns — a mechanism that could be key to long-term weight maintenance.
Questions still open
- Do eating behavior improvements persist after tirzepatide discontinuation?
- Does the additional GIP agonism of tirzepatide contribute to eating behavior changes beyond what GLP-1 alone provides?
- Would higher tirzepatide doses (10-15 mg) produce greater eating behavior changes?
Common questions
Does tirzepatide change how people eat, not just how much they weigh?
Does it matter if you've taken a GLP-1 drug before starting tirzepatide?
Read the original research
Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus.
Journal of diabetes and its complications, 38(7), 108779
Citation
Suzuki, Toru; Sato, Tatsuya; Tanaka, Marenao; Endo, Keisuke; Nakata, Kei; Ogawa, Toshifumi; Hosaka, Itaru; Akiyama, Yukinori; Umetsu, Araya; Furuhashi, Masato. (2024). Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus.. Journal of diabetes and its complications, 38(7), 108779. https://doi.org/10.1016/j.jdiacomp.2024.108779